Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) announced the signing of a non-exclusive distribution and wholesale agreement with Phalanx, Comercializadora e Importadora de Componentes SA DE CV, a pharmaceutical distributor based in Mexico. This agreement, which follows a non-binding Letter of Intent announced on June 24, 2025, establishes a strategic partnership to expand Voyageur's presence in the Mexican healthcare sector, specifically focusing on barium-based contrast media.
Under the agreement, Phalanx will take the lead in registering Voyageur's barium contrast media products with Mexican health regulatory authorities and will distribute these products through its established network. Voyageur will support Phalanx throughout the regulatory process, working collaboratively to advance market access and commercialization. This partnership aligns both companies in a shared vision to grow Voyageur's market presence in Mexico's medical imaging and contrast media markets.
Phalanx is a leading pharmaceutical distributor with a strong presence in Mexico and key Latin American markets that recognize Canadian regulatory approvals. The company provides comprehensive commercial intelligence and strategic market solutions for businesses entering the region. By combining rigorous market analysis with operational execution, Phalanx ensures successful product launches, optimized logistics, and sustainable growth. With deep regulatory expertise and supply chain management, Phalanx accelerates international expansion while minimizing risk, enabling global companies to establish a compliant presence across Latin America.
This partnership represents a key milestone in Voyageur's international growth strategy, further expanding the company's global footprint and supporting access to underserved markets with increasing demand for high-quality contrast media. “This agreement marks a significant step forward in our commercialization roadmap,” said Brent Willis, CEO of Voyageur. “It reflects our continued commitment to expanding global access to our innovative, cost-effective imaging solutions. Latin America is a critical market in our expansion plan, and this partnership lays the groundwork for long-term growth.”
Sales of Voyageur's barium sulfate contrast media products in Mexico and other Latin American countries will be subject to local regulatory approval processes. The distributor is expected to lead the preparation and submission of necessary filings, with support from Voyageur's technical and regulatory team.
Phalanx, based in Mexico, specializes in market entry strategies, distribution, and business development in the health sector in Spanish-speaking Latin America. The Phalanx team has over 20 years of expertise in iodine and gadolinium contrast media for radiology. With decades of experience in the Mexican public health landscape, Phalanx offers Voyageur the ability to enhance its commercial strategy, ensuring regulatory compliance and accelerating market access.
Voyageur Pharmaceuticals is a Canadian public company developing cost-effective imaging contrast media products. The company owns a 100% interest in the Frances Creek Project, which boasts a rare grade mineral suitable for the pharmaceutical marketplace. Voyageur aims to become a vertically integrated company in the radiology contrast media drug market, controlling all primary input costs from raw material sourcing to final production. More information is available at https://voyageurpharmaceuticals.ca.
